Holen Sie sich die Stockscreener-App
3.37
4.26%
-0.15
Vorhandelsmarkt:
3.43
0.06
+1.78%
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion earnings in focus as AI drug platform faces revenue test - Investing.com
Blake Borgeson sells 200,000 Class A shares (RXRX) under Rule 144 - Stock Titan
Recursion Pharmaceuticals Stock Short Interest Rises to 35.49% - Quiver Quantitative
Recursion Pharmaceuticals Inc expected to post a loss of 27 cents a shareEarnings Preview - TradingView
News Flash: 9 Analysts Think Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Earnings Are Under Threat - Sahm
Is It Time To Reconsider Recursion Pharmaceuticals (RXRX) After Recent Share Price Swings? - Yahoo Finance
Does Recursion’s 2026 Update And Board Shift Reframe Its AI Drug Discovery Ambitions For RXRX? - Sahm
What Makes Recursion Pharmaceuticals, Inc. (RXRX) A Strong Penny Stock - Insider Monkey
Recursion Pharmaceuticals (RXRX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Assessing Recursion Pharmaceuticals (RXRX) Valuation As Investor Sentiment Splits On Future Prospects - Sahm
Recursion Pharmaceuticals | DEF 14A: Definitive information statements - Moomoo
Recursion Pharmaceuticals | ARS: Annual Report to Security Holders - Moomoo
Recursion Pharmaceuticals Stock: Founder Chris Gibson to Leave Board as RXRX Nears Q1 Earnings - TechStock²
Recursion Pharmaceuticals : 2026 Proxy Statement - marketscreener.com
Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target Lowered to $10.00 at JPMorgan Chase & Co. - MarketBeat
Recursion Pharmaceuticals Announces Planned Board Leadership Transition - TipRanks
Recursion Pharmaceuticals | DEFA14A: Others - Moomoo
[ARS] RECURSION PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Recursion (RXRX) outlines 2026 virtual meeting, board elections and pay votes - Stock Titan
Recursion founder exits board in June but stays on as adviser - Stock Titan
Recursion Pharmaceuticals | 8-K: Current report - Moomoo
Founder Chris Gibson to exit Recursion Pharmaceuticals (NASDAQ: RXRX) board - Stock Titan
Recursion Announces Board Transition - marketscreener.com
MSN Money - MSN
Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
RXRX stock soars pre-market on Q4 beat, Recursion CEO says company has ‘reached an inflection point’ - MSN
Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6 - marketscreener.com
Recursion opens May 6 earnings call to public questions online - Stock Titan
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
Recursion: No Longer An AI 'Pet Science Project,' But Still A 'Sell' (NASDAQ:RXRX) - Seeking Alpha
Recursion names Vicki Goodman as CMO - MSN
Recursion Pharmaceuticals May Be Losing Ground To Its Peers (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals Projects Massive Growth Amid Clinical Success - HarianBasis.co
Recursion Pharmaceuticals (RXRX) Offers Encouraging Prospects After Setting 2026 Priorities - Insider Monkey
Recursion names Najat Khan CEO, succeeding co-founder Chris Gibson; stock down - MSN
Here's Why Recursion Pharmaceuticals (RXRX) Fell More Than Broader Market - MSN
Why Recursion Pharmaceuticals (RXRX) Is Down 7.1% After AI-Driven Trial Acceleration And Wider EPS Loss Forecast - Yahoo Finance
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Is It Time To Reassess Recursion Pharmaceuticals (RXRX) After Its Recent Share Price Surge - Sahm
10 Most Shorted Penny Stocks to Buy - Insider Monkey
A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention - Yahoo Finance
Recursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com India
Recursion Pharmaceuticals director Gibson sells $144,400 in stock - Investing.com
symbol__ Stock Quote Price and Forecast - CNN
Recursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan
[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan
ETFs Investing in Recursion Pharmaceuticals, Inc. Class A Stocks - TradingView
AI-Driven Target Discovery Breakthrough Might Change The Case For Investing In Recursion Pharmaceuticals (RXRX) - simplywall.st
Christopher Gibson sells Class A shares (NASDAQ: RXRX) in four filings - Stock Titan
Recursion Pharmaceuticals Uses AI to Accelerate Drug Development - HarianBasis.co
Recursion Pharmaceuticals Inc (RXRX): Is AI Strategy Working? - Insider Monkey
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):